Vericel Corporation
VCEL$2.20B
Mid CapNASDAQBiological Products, (No Diagnostic Substances)🇺🇸North AmericaCAMBRIDGE357 employees
Drugs in Pipeline
3
Phase 3 Programs
3
Upcoming Catalysts
0
Next Catalyst
None scheduled
Market Overview
Stock performance and key metrics
VCEL News
Catalyst Timeline
0 upcoming, 1 past
No catalysts found.
Drug Pipeline
MACI
Chondral Defect
autologous cultured chondrocytes on porcine collagen membrane
Articular Cartilage Defect
ixmyelocel-T
Ischemic Dilated Cardiomyopathy (IDCM)
| Drug Name | Phase | Indication | Designations | Patent |
|---|---|---|---|---|
MACI | Phase 3 | Chondral Defect | - | - |
autologous cultured chondrocytes on porcine collagen membrane | Phase 3 | Articular Cartilage Defect | - | - |
ixmyelocel-T | Phase 3 | Ischemic Dilated Cardiomyopathy (IDCM) | - | - |
Chondral Defect
1 drug in this indication
Articular Cartilage Defect
1 drug in this indication
Ischemic Dilated Cardiomyopathy (IDCM)
1 drug in this indication
Peripheral Arterial Disease
1 drug in this indication
Source: CatalystAlert database (ClinicalTrials.gov, SEC EDGAR)
Regulatory Approvals
Data is aggregated from public sources (FDA, SEC, ClinicalTrials.gov). While we strive for accuracy, information may be incomplete, delayed, or contain errors. Terms apply